Patents by Inventor Manuela Kaspar

Manuela Kaspar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190352384
    Abstract: The invention relates to a binding member that binds the Extra Domain-A (ED-A) isoform of fibronectin for the detection and treatment of rheumatoid arthritis.
    Type: Application
    Filed: July 17, 2019
    Publication date: November 21, 2019
    Inventors: Manuela Kaspar, Kathrin Schwager, Eveline Trachsel
  • Patent number: 10385121
    Abstract: The invention relates to a binding member that binds the Extra Domain-A (ED-A) isoform of fibronectin for the detection and treatment of rheumatoid arthritis.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: August 20, 2019
    Assignee: PHILOGEN S.P.A.
    Inventors: Manuela Kaspar, Kathrin Schwager, Eveline Trachsel
  • Publication number: 20170298122
    Abstract: The invention relates to a binding member that binds the Extra Domain-A (ED-A) isoform of fibronectin for the detection and treatment of rheumatoid arthritis.
    Type: Application
    Filed: December 15, 2016
    Publication date: October 19, 2017
    Inventors: Manuela Kaspar, Kathrin Schwager, Eveline Trachsel
  • Patent number: 9556257
    Abstract: The invention relates to a binding member that binds the Extra Domain-A (ED-A) isoform of fibronectin for the detection and treatment of rheumatoid arthritis.
    Type: Grant
    Filed: June 5, 2012
    Date of Patent: January 31, 2017
    Assignee: PHILOGEN S.P.A.
    Inventors: Manuela Kaspar, Kathrin Schwager, Eveline Trachsel
  • Patent number: 9446124
    Abstract: Antibodies which bind an antigen of the bone marrow neovasculature in leukemia patients, for use in treatment and diagnosis of leukemia, in particular the treatment and diagnosis of acute myeloid leukemia (AML).
    Type: Grant
    Filed: March 19, 2014
    Date of Patent: September 20, 2016
    Assignee: Philochem AG
    Inventors: Manuela Kaspar, Christoph Schliemann, Dario Neri
  • Publication number: 20150010498
    Abstract: This invention relates to the treatment of cancer using anti-cancer agents, such as doxorubicin or paclitaxel, in combination with antibody-interleukin 2 (IL2) conjugates which target tenascin-C.
    Type: Application
    Filed: August 12, 2014
    Publication date: January 8, 2015
    Inventors: Eveline Trachsel, Manuela Kaspar, Dario Neri, Jessica Marlind
  • Publication number: 20140341844
    Abstract: This invention relates to the treatment of cancer using anti-ErbB antibodies, such as cetuximab or trastuzumab, in combination with antibody-interleukin 2 (IL2) conjugates which target tenascin-C.
    Type: Application
    Filed: August 4, 2014
    Publication date: November 20, 2014
    Inventors: Manuela Kaspar, Eveline Trachsel
  • Publication number: 20140199238
    Abstract: Antibodies which bind an antigen of the bone marrow neovasculature in leukaemia patients, for use in treatment and diagnosis of leukaemia, in particular the treatment and diagnosis of acute myeloid leukaemia (AML).
    Type: Application
    Filed: March 19, 2014
    Publication date: July 17, 2014
    Inventors: Manuela Kaspar, Christoph Schliemann, Dario Neri
  • Patent number: 8679488
    Abstract: Antibodies which bind an antigen of the bone marrow neovasculature in leukaemia patients, for use in treatment and diagnosis of leukaemia, in particular the treatment and diagnosis of acute myeloid leukaemia (AML).
    Type: Grant
    Filed: August 2, 2010
    Date of Patent: March 25, 2014
    Assignee: Philogen S.p.A.
    Inventors: Manuela Kaspar, Christoph Schliemann, Dario Neri
  • Patent number: 8404814
    Abstract: The present invention relates to fusion proteins comprising an antibody, functional fragment or functional derivative thereof having specific binding affinity to either the extracellular domain of oncofetal fibronectin (ED-B) or at least one of the extracellular domains of oncofetal tenascin fused to a cytokine selected from the group consisting of IL-10, IL15, IL-24 and GM-CSF, functional fragments and functional derivatives thereof. The invention is also directed to the use of at least one of said fusion proteins for the manufacture of a medicament. In particular, the invention concerns the use of said medicament for the treatment of tumors or chronic inflammatory diseases such as atherosclerosis, arthritis and psoriasis.
    Type: Grant
    Filed: May 8, 2007
    Date of Patent: March 26, 2013
    Assignee: Philogen SpA
    Inventors: Dario Neri, Manuela Kaspar, Eveline Trachsel
  • Publication number: 20120244114
    Abstract: The invention relates to a binding member that binds the Extra Domain-A (ED-A) isoform of fibronectin for the detection and treatment of rheumatoid arthritis.
    Type: Application
    Filed: June 5, 2012
    Publication date: September 27, 2012
    Inventors: Manuela Kaspar, Kathrin Schwager, Eveline Trachsel
  • Patent number: 8222377
    Abstract: The invention relates to a binding member that binds the Extra Domain-A (ED-A) isoform of fibronectin for the detection and treatment of rheumatoid arthritis.
    Type: Grant
    Filed: October 27, 2008
    Date of Patent: July 17, 2012
    Assignee: Philogen, S.p.A.
    Inventors: Manuela Kaspar, Kathrin Schwager, Eveline Trachsel
  • Publication number: 20120121506
    Abstract: Antibodies which bind an antigen of the bone marrow neovasculature in leukaemia patients, for use in treatment and diagnosis of leukaemia, in particular the treatment and diagnosis of acute myeloid leukaemia (AML).
    Type: Application
    Filed: August 2, 2010
    Publication date: May 17, 2012
    Inventors: Manuela Kaspar, Christoph Schliemann, Dario Neri
  • Publication number: 20120107270
    Abstract: This invention relates to the treatment of cancer using anti-ErbB antibodies, such as cetuximab or trastuzumab, in combination with antibody-interleukin 2 (IL2) conjugates which target tenascin-C.
    Type: Application
    Filed: June 25, 2010
    Publication date: May 3, 2012
    Inventors: Manuela Kaspar, Eveline Trachsel
  • Publication number: 20110256091
    Abstract: The present invention relates to fusion proteins comprising an antibody, functional fragment or functional derivative thereof having specific binding affinity to either the extracellular domain of oncofetal fibronectin (ED-B) or at least one of the extracellular domains of oncofetal tenascin fused to a cytokine selected from the group consisting of IL-10, IL15, IL-24 and GM-CSF, functional fragments and functional derivatives thereof. The invention is also directed to the use of at least one of said fusion proteins for the manufacture of a medicament. In particular, the invention concerns the use of said medicament for the treatment of tumours or chronic inflammatory diseases such as atherosclerosis, arthritis and psoriasis.
    Type: Application
    Filed: May 8, 2007
    Publication date: October 20, 2011
    Inventors: Dario Neri, Manuela Kaspar, Eveline Trachsel
  • Publication number: 20100260707
    Abstract: The invention relates to a binding member that binds the Extra Domain-A (ED-A) isoform of fibronectin for the detection and treatment of rheumatoid arthritis.
    Type: Application
    Filed: October 27, 2008
    Publication date: October 14, 2010
    Applicant: PHILOGEN S.P.A.
    Inventors: Manuela Kaspar, Kathrin Schwager, Eveline Trachsel
  • Publication number: 20100215615
    Abstract: This invention relates to the treatment of cancer using anti-cancer agents, such as doxorubicin or paclitaxel, in combination with antibody-interleukin 2 (IL2) conjugates which target tenascin-C.
    Type: Application
    Filed: June 25, 2008
    Publication date: August 26, 2010
    Inventors: Eveline Trachsel, Manuela Kaspar, Dario Neri, Jessica Marlind